GlassScriptPhysician profile
Arash Taghavi
NPI 1447647615
$2,814.78
in general payments reported to CMS, 2019-2025
23 companies · $604 in 2025
The $604 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $364 · 2020: $41.47 · 2021: $359 · 2022: $469 · 2023: $486 · 2024: $491 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,580.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $978.75 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $314.11 | 2019-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $271.95 | 2023-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $191.55 | 2019 | |
| Amgen INC. | $164.67 | 2023-2025 | Repatha, Repatha |
| Pfizer INC. | $138.48 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $133.21 | 2021 | |
| Biosense Webster, INC. | $121.40 | 2023 | Carto 3 |
| Lantheus Medical Imaging, INC. | $68.47 | 2019-2021 | |
| Scpharmaceuticals INC. | $64.03 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $60.66 | 2021-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $52.95 | 2021-2025 | Brilinta, Farxiga |
| Novo Nordisk INC | $42.88 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $29.57 | 2023 | Dupixent |
| Baxter Healthcare | $25.43 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $24.67 | 2025 | Attruby |
| Alnylam Pharmaceuticals INC. | $24.09 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $24.09 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $22.13 | 2023 | Arcalyst |
| Amarin Pharma, INC. | $18.20 | 2021 | |
| Medtronic Vascular, INC. | $17.13 | 2020 | |
| Esperion Therapeutics, INC. | $14.62 | 2024 | Nexletol |
| Bardy Diagnostics, INC. | $11.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arash Taghavi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.